KLHL18: A Potential Drug Target (G23276)

Target Name: KLHL18

NCBI ID: G23276

KLHL18

KLHL18: A Potential Drug Target

KLHL18 (FLJ13703) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Kallikrein-related peptidases (KLK) family, which are a group of serine proteases that belong to the subfamily of pro-inflammatory proteases.

KLHL18 has been identified as a potential drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and location in the body make it an attractive target for drug development due to its potential to modulate the immune response and influence the course of various diseases.

One of the key reasons for the potential of KLHL18 as a drug target is its role in the immune response. KLHL18 is a critical regulator of the complement system, which is a group of proteins that work together to help the immune system respond to infections and other threats. The complement system plays a crucial role in activating and enhancing the immune response, and KLHL18 is involved in this process.

Research has shown that KLHL18 is involved in the regulation of the anaphylaxis response, an allergic reaction that can be life-threatening in some individuals. Studies have shown that KLHL18 plays a key role in the regulation of the anaphylaxis response by modulating the activity of immune cells and the production of allergic antibodies.

In addition to its role in the immune response, KLHL18 has also been shown to be involved in the regulation of inflammation and pain. Its presence has been shown in various tissues and has been linked to the regulation of inflammation and pain signaling. This suggests that KLHL18 may be a useful target for drugs that are designed to alleviate inflammation and pain.

The potential of KLHL18 as a drug target is also due to its unique location in the body. KLHL18 is expressed in a variety of tissues throughout the body, including the brain, heart, and kidneys. This makes it an attractive target for drugs that can cross the blood-brain barrier and reach the affected tissue.

In conclusion, KLHL18 is a protein that has the potential to be a drug target due to its involvement in the immune response and its unique location in the body. Its role in the regulation of the complement system and its potential to modulate the immune response make it an attractive target for drugs that are designed to alleviate inflammation and pain. Further research is needed to fully understand the potential of KLHL18 as a drug target and to develop safe and effective treatments.

Protein Name: Kelch Like Family Member 18

Functions: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex required for mitotic progression and cytokinesis (PubMed:23213400). The BCR(KLHL18) E3 ubiquitin ligase complex mediates the ubiquitination of AURKA leading to its activation at the centrosome which is required for initiating mitotic entry (PubMed:23213400). Regulates light-and dark-dependent alpha-transducin localization changes in rod photoreceptors through UNC119 ubiquitination and degradation (By similarity). Preferentially ubiquitinates the unphosphorylated form of UNC119 over the phosphorylated form (By similarity). In the presence of UNC119, under dark-adapted conditions alpha-transducin mislocalizes from the outer segment to the inner part of rod photoreceptors which leads to decreased photoreceptor damage caused by light (By similarity)

The "KLHL18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KLHL18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets